The N501Y mutation, while did not alter the neutralizing antibody binding, presented with a fivefold greater affinity to ACE2, which resulted in a drastically reduced ability of COVID-19 convalescent antisera to neutralize its ACE2 binding. This evidence concerns the gene ACE2 and COVID-19.